How we isolated the TRK oncogene

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

I was very surprised to see in an issue of the NEJM earlier this year that Loxo Oncology had developed a selective TRK inhibitor, larotrectinib, and even more surprised to learn that TRK fusions occur in about 1 percent of all human cancers.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Mariano Barbacid
AXA-CNIO Professor of Molecular Oncology, Centro Nacional de Investigaciones Oncológicas (CNIO), Madrid

YOU MAY BE INTERESTED IN

I write a weekly blog for Georgetown University’s Lombardi Comprehensive Cancer Center community. Here I share an updated version of a blog post I wrote in September 2024, now supplemented by some poems I have written over the years that inspired paintings by my wife Harriet Weiner, who is a much better artist than I am a poet or writer. 
Mariano Barbacid
AXA-CNIO Professor of Molecular Oncology, Centro Nacional de Investigaciones Oncológicas (CNIO), Madrid

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login